Back to top

MTN is excited to share that the DELIVER study has completed enrollment of the first group of 150 participants.

Results of a sub-study of DESIRE called MTN-042B was published on March 31 in PLOS ONE.

The MTN-039 Phase I study of a fast-dissolving rectal insert for HIV prevention has completed follow-up.

View MTN's schedule of presentations, posters, and abstracts for HIVR4P 2021.

MTN is pleased to announce that the final site for the DELIVER study has started screening.

The Behavioral Research Working Group (BRWG) is very excited to share the social and behavioral work completed and lessons learned throughout the life of the MTN.

The DESIRE study has been completed.

MTN is pleased to announce the launch of B-PROTECTED.

Good news about the dapivirine ring.

Results from MTN-041 (the MAMMA study) were published in JIAS.

Good news about HPTN 083.

Spotlight on MTN-041.

A cisgender woman who is eight months pregnant was the first participant enrolled into MTN-042 (DELIVER) which launched mid-February.

MTN-045 has launched.

MTN is pleased to announce the launch of MTN-039.

The Lima, Peru and Blantyre, Malawi sites for MTN-035 have activated.

DESIRE will be discussed at a workshop taking place at the upcoming Biomedical HIV Prevention Summit.

The Chiang Mai site for the MTN-035 rectal microbicide study has been activated.

Final results of HOPE presented at IAS 2019.

MTN-035 (DESIRE) is launched.

MTN is pleased to announce the launch of MTN-038.

MTN is excited to announce that MTN-033 has completed enrollment.

Microbicide Trials Network Research Prominent at 2018 HIV R4P.

MTN is excited to announce the launch of MTN-037.

MTN-033 is launched.

MTN presented preliminary results from the HOPE study (MTN-025) at CROI 2018.

The first-ever study of dapivirine gel as a rectal microbicide has begun.

Study on a vaginal ring for both HIV and pregnancy prevention completed.